儿童神经母细胞瘤无镇静或全身麻醉下进行[18F]MFBG长轴视野PET/CT显像
该前瞻性单中心研究试点纳入10例神经母细胞瘤患儿,在注射[18F]MFBG(1.5-3 MBq/kg)后1小时行长轴视野PET/低剂量CT,无需镇静或全身麻醉,并与[123I]MIBG闪烁显像联合SPECT/CT配对比较。结果显示80%病例[18F]MFBG PET/CT显示更多放射性示踪剂摄取病灶,50%病例SIOPEN评分更高,70%病例Curie评分更高,且全部患儿PET检查中未使用镇静或全身麻醉。
要点
- [18F]MFBG LAFOV PET/CT在儿童神经母细胞瘤显像中可行,全部患儿无需镇静或全身麻醉。
- 配对比较中80%病例[18F]MFBG PET/CT显示更多放射性示踪剂摄取病灶,20%病例病灶数相等。
- SIOPEN评分在50%病例更高,Curie评分在70%病例更高。
核心结论
- 该试点研究证明[18F]MFBG LAFOV PET/CT用于神经母细胞瘤显像具有可行性。
- 与[123I]MIBG闪烁显像联合SPECT/CT相比,[18F]MFBG LAFOV PET/CT显示更多放射性示踪剂摄取病灶、更高的SIOPEN评分和更高的Curie评分,且全部患者避免了全身麻醉和镇静。
- 作者认为,凭借1天方案、显著更短的扫描时间、更高的敏感性和避免全身麻醉与镇静,[18F]MFBG LAFOV PET/CT在未来的分期和疗效评估中有前景,并可能对儿童神经母细胞瘤的治疗决策产生临床影响。
研究设计与样本
- 该研究为前瞻性单中心研究的试点,招募转诊行[123I]MIBG闪烁显像联合SPECT/CT的神经母细胞瘤患儿。
- 在[123I]MIBG闪烁显像联合SPECT/低剂量CT后1周内,行[18F]MFBG LAFOV PET/超低剂量CT,注射后1小时采集(1.5-3 MBq/kg),无需镇静或全身麻醉。
- [18F]MFBG基于螺环碘鎓叶立德前体,采用全自动良好生产规范合规流程生产。
- 本文报告研究可行性及前10例患儿的首批配对扫描结果。
主要发现
- 首批10例患儿(诊断时5例、治疗中2例、监测中2例、复发时1例)的配对扫描中,[18F]MFBG PET/CT在80%病例显示更多放射性示踪剂摄取病灶,20%病例病灶数相等。
- SIOPEN评分在50%病例更高,Curie评分在70%病例更高。
- 椎管内、腹膜后淋巴结和骨髓受累的诊断精确度明显更高。
- 无患儿(中位年龄1.6岁;范围0.1-7.9岁)在PET检查中使用镇静或全身麻醉,而80%在[123I]MIBG闪烁显像联合SPECT/CT中使用全身麻醉。
- 仅2分钟无运动伪影的PET采集时间即可满足10分钟采集时间重建出临床可用图像的数据要求。
局限性
- 该研究为试点研究,仅报告前10例患儿的首批配对扫描结果。
- 作者结论指出[18F]MFBG LAFOV PET/CT在未来的分期和疗效评估中有前景,并可能对治疗决策产生临床影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Meta-[123I]iodobenzylguanidine ([123I]MIBG) scintigraphy with SPECT/CT is the standard of care for diagnosing and monitoring neuroblastoma. Replacing [123I]MIBG with the new PET tracer meta-[18F]fluorobenzylguanidine ([18F]MFBG) and further improving sensitivity and reducing noise in a new long-axial-field-of-view (LAFOV) PET/CT scanner enable increased image quality and a faster acquisition time, allowing examinations to be performed without sedation or general anesthesia (GA). Focusing on feasibility, we present our first experience with [18F]MFBG LAFOV PET/CT and compare it with [123I]MIBG scintigraphy plus SPECT/CT for imaging in neuroblastoma in children. Methods: A pilot of our prospective, single-center study recruited children with neuroblastoma who were referred for [123I]MIBG scintigraphy with SPECT/CT. Within 1 wk of [123I]MIBG scintigraphy and SPECT/low-dose CT, [18F]MFBG LAFOV PET/ultra-low-dose CT was performed 1 h after injection (1.5-3 MBq/kg) without sedation or GA, in contrast to the 24-h postinjection interval needed for scanning with [123I]MIBG, the 2- to 2.5-h acquisition time, and the GA often needed in children less than 6 y old. Based on the spirocyclic iodonium-ylide precursor, [18F]MFBG was produced in a fully automated good manufacturing practice-compliant procedure. We present the feasibility of the study. Results: In the first paired scans of the first 10 children included (5 at diagnosis, 2 during treatment, 2 during surveillance, and 1 at relapse), [18F]MFBG PET/CT scan showed a higher number of radiotracer-avid lesions in 80% of the cases and an equal number of lesions in 20% of the cases. The SIOPEN score was higher in 50% of the cases, and the Curie score was higher in 70% of the cases. In particular, intraspinal, retroperitoneal lymph node, and bone marrow involvement was diagnosed with much higher precision. None of the children (median age, 1.6 y; range, 0.1-7.9 y) had sedation or GA during the PET procedure, whereas 80% had GA during [123I]MIBG scintigraphy with SPECT/CT. A PET acquisition time of only 2 min without motion artifacts was the data requirement of the 10-min acquisition time for reconstruction to provide a clinically useful image. Conclusion: This pilot study demonstrates the feasibility of performing [18F]MFBG LAFOV PET/CT for imaging of neuroblastoma. Further, an increased number of radiotracer-avid lesions, an increased SIOPEN score, and an increased Curie score were seen on [18F]MFBG LAFOV PET/CT compared with [123I]MIBG scintigraphy with SPECT/CT, and GA and sedation was avoided in all patients. Thus, with a 1-d protocol, a significantly shorter scan time, a higher sensitivity, and the avoidance of GA and sedation, [18F]MFBG LAFOV PET/CT shows promise for future staging and response assessment and may also have a clinical impact on therapeutic decision-making for children with neuroblastoma.
引用
- Borgwardt L, Brok J, Andersen KF, et al. Performing [18F]MFBG Long-Axial-Field-of-View PET/CT Without Sedation or General Anesthesia for Imaging of Children with Neuroblastoma. J Nucl Med. 2024. PMID: 38960713. doi:10.2967/jnumed.123.267256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。